Related Experiment Videos
[The fibrinolytic system and its activators]
1Abteilung Innere Medizin III, Universität Ulm.
Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete
|June 1, 1993
Summary
The human fibrinolysis system dissolves blood clots using plasmin. Thrombolytic therapies, including tissue plasminogen activator (t-PA), enhance this process to reopen blocked vessels.
Area of Science:
- Biochemistry
- Physiology
- Pharmacology
Context:
- The human fibrinolysis system is a crucial blood process for dissolving clots.
- Intravascular thrombosis poses significant health risks, necessitating effective treatments.
Purpose:
- To explain the mechanisms of the human fibrinolysis system.
- To review current and developing thrombolytic therapies.
- To highlight advancements in improving thrombolytic agents.
Summary:
- Fibrinolysis involves plasmin, generated from plasminogen, to break down blood clots.
- Available thrombolytics include streptokinase, APSAC, urokinase, and tissue plasminogen activator (t-PA).
- t-PA offers relative fibrin selectivity, unlike systemic activators; newer agents and mutants are under development.
Impact:
- Understanding fibrinolysis is key to developing targeted therapies for thromboembolic diseases.
- Advancements in thrombolytic agents aim to improve efficacy, safety, and patient outcomes.
- Future developments focus on enhanced thrombus affinity and prolonged half-life for improved therapeutic potential.